Dimiitrios P. Kontoyiannis, MD, ScD, PhD (hon)

The University of Texas MD Anderson Cancer Center

Disclosure(s): AbbVie: Advisor/Consultant; Astellas Pharma: Advisor/Consultant, Grant/Research Support, Honoraria; Cidara Therapeutics: Advisor/Consultant; Gilead Sciences: Advisor/Consultant, Grant/Research Support, Honoraria; Merck: Advisor/Consultant

Poster(s):

• 465 - A Multifaceted and Multi-Institutional Analysis of the COVID19-Associated Mucormycosis Outbreak in the Delhi Area Indicates the Simultaneous Convergence of Multiple Risk Factors
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 482 - The modern face of esophageal candidiasis (EC) in an oncology center: Analysis of 323 cancer patients with EC
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 499 - Immunotherapy with Pattern Recognition Receptor Agonists Improves Morbidity and Mortality in a Corticosteroid-Immunosuppressed Murine Model of Influenza-Associated Pulmonary Aspergillosis
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 2102 - Common co-occurence in the respiratory tract of Mucorales with Gram-negative rods in patients with hematologic malignancy and sinopulmonary mucormycosis
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 2114 - Invasive fusariosis in the era of mold active azoles and molecular targeted chemotherapy: Increasing incidence and lack of improved outcomes
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET